Oxaliplatin, as previously studied in the paper, is a derivative of Cisplatin that is effective in treating the Lewis Lung Carcinoma (LLC)4. As it can actively induce immunogenic cell death of the cancer cells, and result in apoptosis, which increases the therapeutic efficacy in the LLC cancer treatment.4 Merkel cell caner is a type of skin cancer that is rare but highly aggressive, with high metastasizing and reoccurring rate. In this study, we aim the determine the potential of Oxaliplatin to induce apoptosis and ICD in cancerous Merkel cell line MCC1, in associate with the PD-1 inhibitor Nivolumab. The cancer cells will be treated with Oxaliplatin at concentrations 1 mM, 10 mM, or 100 mM. Avelumab and PBS will be used as the positive and negative control, respectively. The treated cells will be measured by checking for tumor size change in confocal microscopy and MTT assay, measuring the ICD using flow cytometry analysis of CRT expression, and conducting Western Blot for Cytokeratin 20 expression. The results of the study will provide insights on the potential of Oxaliplatin as a treatment of Merkel Cell Cancer in the future.
Keywords: Merkel Cell Cancer; Oxaliplatin; PD-1; PD-L1; T cells.